Timothy G. Whitten
Directeur Général chez Insmed Ltd.
Profil
Timothy G.
Whitten is currently the President & Chief Executive Officer at Insmed Ltd.
and the President, Chief Executive Officer & Director at Taiho Oncology, Inc. Previously, he held positions as the President, Chief Executive Officer & Director at Insmed, Inc. from 2010 to 2011, the President & Chief Executive Officer at Transave, Inc., the Vice President-Global Marketing at Bristol Myers Squibb Co., and the Senior VP-Commercial Operations & Development at Pharmacyclics LLC.
Mr. Whitten holds an MBA degree from the University of Virginia and an undergraduate degree from West Virginia University.
Postes actifs de Timothy G. Whitten
| Sociétés | Poste | Début |
|---|---|---|
Insmed Ltd.
 Insmed Ltd. Pharmaceuticals: MajorHealth Technology Insmed Ltd. develops and manufactures pharmaceutical products for the treatment of lung diseases. Its products are used for the site-specific treatment of serious lung diseases such as pulmonary infections in cystic fibrosis patients and cancers affecting the lung. The company is located in London, the United Kingdom. | Directeur Général | 10/06/2009 |
Taiho Oncology, Inc.
 Taiho Oncology, Inc. Pharmaceuticals: MajorHealth Technology Taiho Oncology, Inc. develops and markets anti-metabolite cancer drugs. It focuses on cornerstone anti-metabolites as well as on targeted small molecule inhibitors. The firm engages in the research, development, and manufacturing of pharmaceutical products in the fields of oncology, allergy and immunology, and urology. It also offers nutrient tonic and crude drug gastrointestinal remedy products. The company was founded in 2002 and is headquartered in Princeton, NJ. | Directeur Général | - |
Anciens postes connus de Timothy G. Whitten
| Sociétés | Poste | Fin |
|---|---|---|
| INSMED INCORPORATED | President | 10/09/2012 |
| BRISTOL-MYERS SQUIBB COMPANY | Sales & Marketing | - |
Transave, Inc.
 Transave, Inc. Pharmaceuticals: MajorHealth Technology Transave, Inc. is a biopharmaceutical company focused on developing innovative, inhaled pharmaceuticals for the site-specific treatment of serious lung diseases such as pulmonary infections in cystic fibrosis patients and cancers affecting the lung. They are committed to significantly improving the quality of life and healthcare of patients suffering from these life-threatening diseases. Its operating principles are centered on teamwork, openness, mutual respect, diversity of opinion, trust, accountability and innovative science. They are developing products based on Transave's proprietary liposomal technology designed specifically for lung delivery. Its focus is on reformulating off-patent, established drugs into unique liposomal technology - based inhaled pharmaceuticals for the localized, site-specific treatment of serious lung diseases. Transave's proprietary liposomal technology allows for the sustained release of a drug in the lung's microenvironment. By remaining in the lungs for a prolonged period and potentially minimizing systemic exposure, Transave's liposomal technology offers the potential for changing the product profile, improving delivery of the compound to the lung and enhancing the therapeutic index of established pharmaceuticals. | President | - |
| PHARMACYCLICS, INC. | Corporate Officer/Principal | - |
Formation de Timothy G. Whitten
| University of Virginia | Masters Business Admin |
| West Virginia University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| INSMED INCORPORATED | Health Technology |
| Entreprise privées | 4 |
|---|---|
Pharmacyclics LLC
 Pharmacyclics LLC Pharmaceuticals: MajorHealth Technology Pharmacyclics LLC engages in developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. It has product candidates in clinical development and several preclinical molecules in optimization. The company was founded by Jonathan Sessler and Richard Miller in 1991 and is headquartered in Sunnyvale, CA. | Health Technology |
Transave, Inc.
Transave, Inc. Pharmaceuticals: MajorHealth Technology Transave, Inc. is a biopharmaceutical company focused on developing innovative, inhaled pharmaceuticals for the site-specific treatment of serious lung diseases such as pulmonary infections in cystic fibrosis patients and cancers affecting the lung. They are committed to significantly improving the quality of life and healthcare of patients suffering from these life-threatening diseases. Its operating principles are centered on teamwork, openness, mutual respect, diversity of opinion, trust, accountability and innovative science. They are developing products based on Transave's proprietary liposomal technology designed specifically for lung delivery. Its focus is on reformulating off-patent, established drugs into unique liposomal technology - based inhaled pharmaceuticals for the localized, site-specific treatment of serious lung diseases. Transave's proprietary liposomal technology allows for the sustained release of a drug in the lung's microenvironment. By remaining in the lungs for a prolonged period and potentially minimizing systemic exposure, Transave's liposomal technology offers the potential for changing the product profile, improving delivery of the compound to the lung and enhancing the therapeutic index of established pharmaceuticals. | Health Technology |
Insmed Ltd.
Insmed Ltd. Pharmaceuticals: MajorHealth Technology Insmed Ltd. develops and manufactures pharmaceutical products for the treatment of lung diseases. Its products are used for the site-specific treatment of serious lung diseases such as pulmonary infections in cystic fibrosis patients and cancers affecting the lung. The company is located in London, the United Kingdom. | Health Technology |
Taiho Oncology, Inc.
Taiho Oncology, Inc. Pharmaceuticals: MajorHealth Technology Taiho Oncology, Inc. develops and markets anti-metabolite cancer drugs. It focuses on cornerstone anti-metabolites as well as on targeted small molecule inhibitors. The firm engages in the research, development, and manufacturing of pharmaceutical products in the fields of oncology, allergy and immunology, and urology. It also offers nutrient tonic and crude drug gastrointestinal remedy products. The company was founded in 2002 and is headquartered in Princeton, NJ. | Health Technology |